Cardiac Performance Evaluation in Patients with Muscular Dystrophy - Takeaways - MDSpire

Cardiac Performance Evaluation in Patients with Muscular Dystrophy

  • By

  • Naomi Khanna

  • Joseph Mahgerefteh

  • Noah Elkins

  • Daphne T. Hsu

  • Jacqueline M. Lamour

  • Leslie Delfiner

  • Induja Gajendran

  • Neha Bansal

  • February 20, 2026

  • 0 min

Share

  • 1

    Dilated cardiomyopathy frequently occurs in adolescents and young adults with muscular dystrophies, often preceding clinical heart failure.

  • 2

    Ventriculoarterial coupling (VAC) is a key measure of cardiovascular efficiency, reflecting the relationship between ventricular performance and arterial load.

  • 3

    This study aimed to evaluate VAC in muscular dystrophy patients, hypothesizing that VAC would be more abnormal in those with worse disease phenotypes.

  • 4

    A total of 46 muscular dystrophy patients were included, with a median follow-up of 4.1 years and a majority exhibiting the Duchene phenotype.

  • 5

    At initial echocardiograms, 70% of patients were on oral steroids, and 65% were receiving ACE inhibitors or ARBs, with mean LVEF at 58 ± 8%.

Original Source(s)

Related Content